Gyre Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
GYRE Nasdaq 2834 www.gyretx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Gyre Therapeutics, Inc.

Public companies account for 71% of Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) ownership, while individual investors account for 19% - Jun 20th, 2025 5:21 am
Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China - Jun 10th, 2025 5:00 am
Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - May 29th, 2025 2:01 pm
Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock - May 22nd, 2025 6:57 pm
Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock - May 22nd, 2025 2:02 pm
Gyre Therapeutics’ Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China - May 22nd, 2025 2:01 pm
Gyre Therapeutics First Quarter 2025 Earnings: EPS: US$0.031 (vs US$0.09 in 1Q 2024) - May 10th, 2025 8:31 am
Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - May 9th, 2025 4:00 am
A Note On Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) ROE and Debt To Equity - May 7th, 2025 4:45 am
Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications - Mar 31st, 2025 5:00 am
We Think You Should Be Aware Of Some Concerning Factors In Gyre Therapeutics' (NASDAQ:GYRE) Earnings - Mar 27th, 2025 12:40 pm
Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology - Mar 27th, 2025 5:00 am
Gyre Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Mar 19th, 2025 4:54 am
Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - Mar 17th, 2025 2:15 pm
Exploring High Growth Tech Stocks In The US March 2025 - Mar 12th, 2025 5:08 am
Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors - Jan 6th, 2025 5:00 am
Gyre Therapeutics Third Quarter 2024 Earnings: EPS: US$0.013 (vs US$0.68 loss in 3Q 2023) - Nov 15th, 2024 4:27 am
Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update - Nov 13th, 2024 4:00 am
Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis - Oct 22nd, 2024 2:05 pm
Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) market cap dropped US$51m last week; Public companies bore the brunt - Oct 4th, 2024 8:20 am